Diagnosing psychiatric disorders is difficult owing to poor understanding of the exact causes and mechanisms underlying them. This not only leads to problematic diagnoses, it also creates challenges for companies trying to develop psychiatric disorder treatments.

Clinicians - and companies running clinical trials - currently have to rely on qualitative clinical rating scales of emotion that can be inherently unreliable. At the same time, very few brain dysfunction biomarkers can be detected by analyzing blood samples owing to